NDA 203388 · Genentech
Erivedge
Vismodegib · Oral · Hedgehog Pathway Inhibitor
NovelPriority reviewLast checked: Nov 20, 2026Latest source record: Mar 27, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2012
Jan 30, 2012
Approved uses
2
Original approval plus efficacy supplements
Registered trials
86
0 Phase 3, 11 recruiting
FAERS reports
8,927
3,811 serious, 998 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: EMBRYO-FETAL TOXICITY ERIVEDGE can cause embryo-fetal death or severe birth defects when administered to a pregnant woman. ERIVEDGE is embryotoxic, fetotoxic, and teratogenic in animals. Teratogenic effects included severe midline defects, missing digits, and other irreversible malformations [see Warnings and Precautions (5.1) , Use in Specific Populations (8.1) ] . Verify the pregnancy status of females of reproductive potential within 7 days prior to initiating ERIVEDGE. Advise pregnant women of the potential risks to a fetus. Advise females of reproductive potential to use effective contraception during and after ERIVEDGE [ see Dosage and Administration (2.1) , Warnings and Precautions (5.1) , Use in Specific Populations (8.1 , 8.3) ] . Advise males of the potential risk of ERIVEDGE exposure through semen and to use condoms with a pregnant partner or a female partner of...
What it is approved for
From the label in effect Dec 2, 2024.
ERIVEDGE is indicated for the treatment of adults with metastatic basal cell carcinoma, or with locally advanced basal cell carcinoma that has recurred following surgery or who are not candidates for surgery and who are not candidates for radiation. ERIVEDGE ® (vismodegib) is a hedgehog pathway inhibitor indicated for the treatment of adults with metastatic basal cell carcinoma, or with locally advanced basal cell carcinoma that has recurred following surgery or who are not candidates for surgery and who are not candidates for radiation. ( 1 )
Mechanism: Vismodegib is an inhibitor of the Hedgehog pathway. Vismodegib binds to and inhibits Smoothened, a transmembrane protein involved in Hedgehog signal transduction.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jan 18, 2019 Supplement 12 · Efficacy LabelLetter
- Jan 30, 2012 Original approval · Type 1 - New Molecular Entity · priority review NovelLetterLabelReview
1 products under this application
- ERIVEDGE · VISMODEGIB 150MG · CAPSULE, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Vismodegib" as an intervention, any sponsor and status, largest first.
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)Active, not recruiting
National Cancer Institute (NCI)NIH
NCT02465060 · 6,452 participants (planned) · Start Aug 17, 2015 · Primary completion Dec 31, 2027
Drug: Adavosertib; Afatinib and 30 more · For: Advanced Lymphoma; Advanced Malignant Solid Neoplasm; Bladder Carcinoma and 49 more
Sites: Birmingham, Alabama; Fairhope, Alabama; Mobile, Alabama · 1,410 sites in all
Oslo University HospitalAcademic, hospital or other
NCT04817956 · 3,000 participants (planned) · Start Apr 1, 2021 · Primary completion Mar 30, 2040
Drug: Atezolizumab · For: Cancer Metastatic
Sites: Ålesund, Norway; Bergen, Norway; Bodø, Norway · 17 sites in all
The Netherlands Cancer InstituteAcademic, hospital or other
NCT02925234 · 1,550 participants (planned) · Start Aug 2016 · Primary completion Sep 2027
Drug: Panitumumab; Olaparib and 35 more · For: Cancer; Tumors; Neoplasm and 1 more
Sites: Alkmaar, Netherlands; Almelo, Netherlands; Amersfoort, Netherlands · 36 sites in all
- STEVIE: A Study of Vismodegib in Patients With Locally Advanced or Metastatic Basal Cell CarcinomaCompleted
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT01367665 · 1,232 participants · Start Jul 1, 2011 · Primary completion Jun 14, 2017
Drug: vismodegib · For: Basal Cell Carcinoma
Sites: Buenos Aires, Argentina; Kogarah, Australia; Westmead, Australia · 181 sites in all
- Molecularly Tailored Therapy in Advanced Pancreatic CancerPivotal-lookingNot yet recruiting
Herlev HospitalAcademic, hospital or other
NCT07802418 · 1,200 participants (planned) · Start Oct 2026 · Primary completion Jun 2031
Drug: Arm 1: Molecularly Tailored Therapy; Arms 2: Standard-of-Care Therapy and 1 more · For: Pancreatic Cancer
Sites: Aalborg, Denmark; Aarhus, Denmark; Herlev, Denmark · 4 sites in all
Canadian Cancer Trials GroupResearch network
NCT03297606 · 720 participants (planned) · Start Mar 23, 2018 · Primary completion Dec 31, 2026
Drug: Olaparib; Dasatinib and 12 more · For: Lymphoma, Non-Hodgkin; Multiple Myeloma; Advanced Solid Tumors
Sites: Edmonton, Canada; Kelowna, Canada; Vancouver, Canada · 10 sites in all
Genentech, Inc.Roche (Genentech) (RHHBY)
NCT02091141 · 673 participants · Start Apr 14, 2014 · Primary completion May 24, 2023
Drug: Trastuzumab; Pertuzumab and 6 more · For: Neoplasms; Solid Tumors; Biliary Cancer and 2 more
Sites: Goodyear, Arizona; Phoenix, Arizona; Springdale, Arkansas · 60 sites in all
- A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed MedulloblastomaActive, not recruiting
St. Jude Children's Research HospitalAcademic, hospital or other
NCT01878617 · 660 participants · Start Jun 23, 2013 · Primary completion Oct 13, 2028
Drug: Cyclophosphamide; Cisplatin and 4 more · For: Medulloblastoma
Sites: Palo Alto, California; San Diego, California; New Haven, Connecticut · 23 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- muscle spasms2,074
- alopecia1,406
- ageusia1,018
- fatigue980
- death757
- dysgeusia748
- weight decreased741
- nausea722
- decreased appetite708
- diarrhoea476
- constipation383
- off label use383
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2010 | 1 |
| 2011 | 3 |
| 2012 | 122 |
| 2013 | 241 |
| 2014 | 292 |
| 2015 | 468 |
| 2016 | 631 |
| 2017 | 1,465 |
| 2018 | 869 |
| 2019 | 773 |
| 2020 | 710 |
| 2021 | 663 |
| 2022 | 741 |
| 2023 | 674 |
| 2024 | 666 |
| 2025 | 385 |
| 2026 | 223 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Erivedge (Vismodegib)
2024 spending
$117M
Beneficiaries
1,870
9,065 claims
Per beneficiary
$62,444
$474.32 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $138,064,673 |
| 2021 | $140,212,165 |
| 2022 | $124,771,563 |
| 2023 | $102,945,428 |
| 2024 | $116,769,824 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Vismodegib.
Rudin CM · Clin Cancer Res 2012 · Clinical Trial, Phase II, Multicenter Study
- Vismodegib in Gorlin-Goltz syndrome: A systematic review.
Palmeiro AG, Carvalho M, Gonçalves Castro C, et al. · Australas J Dermatol 2024 · Systematic Review
- Management of Skin Cancer in the High-Risk Patient.
Behan JW, Sutton A, Wysong A · Curr Treat Options Oncol 2016 · Meta-Analysis, Review
- Exploring vismodegib: A non-surgical breakthrough in the management of advanced periocular basal cell carcinoma.
Lavasidis G, Tzamalis A, Tsinopoulos I, et al. · Cancer Treat Res Commun 2024 · Systematic Review
- Alopecia in patients treated with molecularly targeted anticancer therapies.
Belum VR, Marulanda K, Ensslin C, et al. · Ann Oncol 2015 · Meta-Analysis, Research Support, N.I.H., Extramural
- Molecularly matched targeted therapies plus radiotherapy in glioblastoma: the phase 1/2a N2M2 umbrella trial.
Wick W, Lanz LM, Wick A, et al. · Nat Med 2025 · Clinical Trial, Phase I, Clinical Trial, Phase II
Sponsor: Roche (Genentech)
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.